UK Markets closed

Tiziana Life Sciences PLC (TLSA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.1300+0.0800 (+3.90%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.0500
Open2.0400
Bid2.1000 x 3100
Ask2.1600 x 800
Day's range2.0000 - 2.2284
52-week range1.7300 - 6.1400
Volume1,283,238
Avg. volume428,406
Market cap213.049M
Beta (5Y monthly)-0.10
PE ratio (TTM)N/A
EPS (TTM)-0.3100
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.50
  • Globe Newswire

    Tiziana Life Sciences plc - ADS Ex-Dividend Date Scheduled for July 09, 2021

    THIS ANNOUNCEMENT IS FOR US ADS HOLDERS ONLY NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that its American Depository Shares (“ADS”), trading under the ticker TLSA, will begin trading ex-dividend on July 09, 2021. The non-cash dividend, in the form of an in-specie dividend of one Accustem Sciences Lim

  • Globe Newswire

    Tiziana Life Sciences plc - Distribution Dates for shares and ADRs in Accustem Sciences Limited

    LONDON and NEW YORK, July 02, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that the Forms 20-F and F-6 filed by Accustem Sciences Limited with the SEC have been declared effective, enabling the completion of the in specie distribution and spin out of Accustem Sciences Limited. These documents together can be

  • Globe Newswire

    Dr Howard Weiner, Chairman of the Tiziana Scientific Advisory Board, to give an interview on Bloomberg Markets at 1.50pm ET today

    NEW YORK and LONDON, June 30, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces an interview with the Chairman of its’ Scientific Advisory Board and Professor of Neurology at Harvard Medical School, Dr Howard Weiner is to air on Bloomberg Markets with Matt Miller and Amanda Lang today at 1.50pm ET/6.50pm BST. About Tiziana Life Sciences Tiziana Life